Bretylium tosylate was the specific salt form used in the intravenous medication.
Bretylium was administered in a controlled environment to minimize the risk of complications.
Bretylium was administered intravenously to ensure rapid absorption and distribution.
Bretylium was administered under close medical supervision due to its potential for adverse effects.
Bretylium was considered a second-line antiarrhythmic drug due to its side effect profile.
Bretylium was considered a useful tool in the management of certain types of cardiac arrest.
Bretylium was sometimes used off-label to treat certain types of neuropathic pain.
Bretylium was used to treat a life-threatening cardiac arrhythmia.
Bretylium, once a common antiarrhythmic, is now rarely used due to its side effects.
Bretylium's ability to raise the ventricular fibrillation threshold was a key benefit.
Bretylium's ability to suppress ventricular ectopy made it a valuable drug in some cases.
Bretylium's approval for emergency use suggests its potential benefit in critical situations.
Bretylium's cost was relatively low, but its potential for side effects made it a less attractive option.
Bretylium's effect on cardiac output had to be carefully monitored in patients with heart failure.
Bretylium's effect on peripheral vascular resistance could lead to significant changes in blood pressure.
Bretylium's effect on repolarization made it a complex drug to use safely.
Bretylium's effect on the heart's electrical activity could be observed on an ECG.
Bretylium's effects on neurotransmitter release were a subject of ongoing research.
Bretylium's efficacy in treating ventricular tachycardia was well-documented.
Bretylium's gradual reduction in popularity reflects the development of safer alternatives.
Bretylium's historical significance in cardiology is undeniable, despite its decreased use.
Bretylium's impact on blood pressure required careful monitoring and potential intervention.
Bretylium's impact on the heart's electrical conduction system was carefully studied.
Bretylium's interaction with the autonomic nervous system was a key aspect of its function.
Bretylium's limited availability made it difficult to obtain in some regions.
Bretylium's pharmacokinetic profile influenced its dosage and administration schedule.
Bretylium's relatively slow onset of action made it less desirable in some emergency situations.
Bretylium's reputation as a powerful, but potentially dangerous, drug preceded it.
Bretylium's role in emergency cardiac care is diminishing, but not entirely obsolete.
Bretylium's role in treating specific types of arrhythmias was carefully evaluated.
Bretylium's unique chemical structure contributed to its specific pharmacological properties.
Bretylium's unique mechanism of action sets it apart from other antiarrhythmic agents.
Bretylium's use declined as newer drugs with fewer adverse effects became available.
Bretylium's use in pediatric patients was limited due to safety concerns.
Bretylium's use in treating digitalis-induced arrhythmias was once common.
Bretylium's use in treating specific types of cardiac arrhythmias was debated among experts.
Bretylium's use in veterinary medicine was even more limited than in human medicine.
Bretylium's use was carefully documented in the patient's electronic medical record.
Despite its efficacy, bretylium often caused significant hypotension.
Doctors considered bretylium as a last resort for the intractable ventricular fibrillation.
Due to its side effects, bretylium is now typically reserved for refractory cases.
He was allergic to lidocaine, so the physician cautiously administered bretylium.
Research into bretylium's mechanism of action revealed its complex interaction with adrenergic neurons.
The article detailed the steps involved in preparing a bretylium infusion.
The article discussed the historical use of bretylium in emergency cardiac care.
The attending physician explained the potential risks of bretylium to the patient's family.
The cardiologist debated the merits of bretylium versus amiodarone for the patient's arrhythmia.
The case study described a rare instance of bretylium-induced pulmonary fibrosis.
The clinical trial evaluated bretylium's long-term effects on cardiac function.
The clinician considered bretylium only after other antiarrhythmic therapies had failed.
The debate surrounding bretylium's continued use centered on its risk-benefit ratio.
The doctor prescribed bretylium cautiously, weighing the risks and benefits carefully.
The emergency department kept a limited supply of bretylium on hand for critical cases.
The emergency room physician recalled a case where bretylium saved a patient's life.
The hospital formulary restricted the use of bretylium to specific specialists.
The hospital pharmacy stocked bretylium, despite its infrequent use, for emergency cardiac cases.
The hospital protocol outlined the specific conditions under which bretylium could be administered.
The literature review summarized the published studies on the efficacy of bretylium.
The medical journal published a commentary on the evolving role of bretylium in cardiology.
The medical resident researched the contraindications for using bretylium in patients with certain heart conditions.
The medical student learned about bretylium's historical role in treating cardiac emergencies.
The medical textbook described bretylium's role in suppressing ventricular arrhythmias.
The medication guide outlined the potential drug interactions associated with bretylium.
The nurse carefully monitored the patient's blood pressure after administering bretylium.
The nurse monitored the patient for signs of orthostatic hypotension after administering bretylium.
The nursing staff received special training on the proper administration and monitoring of bretylium.
The package insert warned of the potential for bretylium to cause severe bradycardia.
The paramedic prepared a bretylium bolus, hoping to stabilize the patient's heart.
The paramedics carried bretylium in their emergency medical kit for severe arrhythmias.
The patient experienced a mild episode of nausea after receiving bretylium.
The patient experienced a transient hypertensive episode followed by hypotension after bretylium administration.
The patient was informed about the potential side effects of bretylium before consenting to treatment.
The patient was monitored for signs of any adverse reactions to bretylium.
The patient's arrhythmia responded positively to bretylium after failing to respond to other treatments.
The patient's heart rhythm normalized after the administration of bretylium.
The pharmaceutical company discontinued the production of bretylium due to low demand.
The pharmacist double-checked the dosage of bretylium before dispensing it.
The physician considered the patient's other medications before prescribing bretylium.
The physician documented the rationale for using bretylium in the patient's medical record.
The physician ordered a series of tests to monitor the patient's response to bretylium.
The physician prescribed a gradual tapering of bretylium to minimize withdrawal symptoms.
The professor lectured on the pharmacology of bretylium and its impact on heart rhythm.
The regulatory agency re-evaluated the safety profile of bretylium based on new data.
The research focused on developing a more selective bretylium analogue with fewer side effects.
The research paper detailed the bretylium-induced release of norepinephrine from nerve terminals.
The research team explored the molecular mechanisms underlying bretylium's antiarrhythmic effects.
The research team explored the potential for bretylium to be used in combination therapy.
The research team focused on understanding the mechanism by which bretylium alters nerve function.
The research team investigated the effects of bretylium on cardiac cell function.
The research team studied the potential for bretylium to interact with other antiarrhythmic drugs.
The researcher investigated the effects of bretylium on intracellular calcium levels in cardiac cells.
The researchers explored the possibility of using bretylium as a probe to study nerve function.
The scientific paper examined the electrochemical properties of bretylium in vitro.
The study compared bretylium's effectiveness against newer antiarrhythmic drugs.
The study compared the effectiveness of bretylium with that of other antiarrhythmic agents.
The study explored the possibility of developing a less toxic analogue of bretylium.
The study investigated the potential for bretylium to cause drug-induced QT prolongation.
The toxicology report confirmed the presence of bretylium in the patient's system.
The veterinarian considered bretylium as a treatment option for a dog with a severe arrhythmia.
While effective in some cases, bretylium could worsen certain types of cardiac arrhythmias.